title: Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors.
abstract: A group of 18 patients with advanced cancer were entered on a phase I study of a 120-h continuous intravenous infusion of hydroxyurea. The dose of hydroxyurea was escalated in cohorts of patients from 1 to 2 to 3.2 g/ m2 per day. The primary dose-limiting toxicity was neutropenia, often accompanied by leukopenia, thrombocytopenia and generalized skin rash. Prophylactic treatment of patients with dexamethasone and diphenhydramine hydrochloride prevented the skin rash, but not the hematopoietic toxicities. The pharmacokinetics of hydroxyurea were studied in all patients. The steady-state concentrations of hydroxyurea were linearly correlated with the dose (R2 = 0.71, n = 18, P < 0.0001). The mean +/- SE concentrations were 93 +/- 16, 230 +/- 6 and 302 +/- 27 microM at 1, 2 and 3.2 g/m2 per day, respectively. The mean +/- SE renal and nonrenal clearances of hydroxyurea were 2.14 +/- 0.18 and 3.39 +/- 0.28 l/h per m2 (n = 16), neither of which correlated with the dose. The concentration of hydroxyurea in plasma decayed monoexponentially with a mean +/- SE half-life of 3.25 +/- 0.18 h (n = 17). The steady-state concentration of hydroxyurea was > 200 microM in all nine patients treated at 2 g/m2 per day, a dose which was well tolerated for 5 days. We recommend this dose for phase II trials in combination with other antineoplastic agents.
authors.affiliation: Division of Pediatrics, City of Hope Cancer Research Center, Duarte, CA 91010, USA. enewman@smtplink.coh.org
authors.forename: E M
authors.initials: EM
authors.lastname: Newman
authors.forename: M
authors.initials: M
authors.lastname: Carroll
authors.forename: S A
authors.initials: SA
authors.lastname: Akman
authors.forename: W
authors.initials: W
authors.lastname: Chow
authors.forename: P
authors.initials: P
authors.lastname: Coluzzi
authors.forename: V
authors.initials: V
authors.lastname: Hamasaki
authors.forename: L A
authors.initials: LA
authors.lastname: Leong
authors.forename: K A
authors.initials: KA
authors.lastname: Margolin
authors.forename: R J
authors.initials: RJ
authors.lastname: Morgan
authors.forename: J W
authors.initials: JW
authors.lastname: Raschko
authors.forename: S
authors.initials: S
authors.lastname: Shibata
authors.forename: G
authors.initials: G
authors.lastname: Somlo
authors.forename: M
authors.initials: M
authors.lastname: Tetef
authors.forename: Y
authors.initials: Y
authors.lastname: Yen
authors.forename: C W
authors.initials: CW
authors.lastname: Ahn
authors.forename: J H
authors.initials: JH
authors.lastname: Doroshow
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D004334:Drug Administration Schedule; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D007262:Infusions, Intravenous; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D009503:Neutropenia / Q000139:chemically induced
chemical_list: D000970:Antineoplastic Agents; D006918:Hydroxyurea